Join hosts to learn about the recently published American Headache Society position statement update regarding calcitonin gene-related peptide (CGRP)-targeting therapies as first-line treatments for migraine prevention. Our expert panel will discuss how this statement will hopefully lead to earlier access for patients, without having to fail other therapies currently available. Discussion will include how the paper was developed through real-world data about patient experiences, why it is important to patients and how you can utilize the updated position to access care earlier.
Attendees will also hear about the American Migraine Foundation’s recent accomplishments, plans for the future and other promising developments in migraine advocacy and education.
The event will feature AMF Chair and Vice Chair, Dr Christine Lay and Nim Singh, along with AHS colleagues Drs Kathleen Digre and Rashmi Halker Singh and patient advocate Lindsey de los Santos.
Register
